Effects of mogamulizumab in adult T‐cell leukemia/lymphoma in clinical practice. (10th March 2017)

• Record Type: Journal Article
• Authors: Sekine, Masaaki; Kubuki, Yoko; Kameda, Takuro; Takeuchi, Masanori; Toyama, Takanori; Kawano, Noriaki; Maeda, Kouichi; Sato, Seiichi; Ishizaki, Junzo; Kawano, Hiroshi; Kamiunten, Ayako; Akizuki, Keiichi; Tahira, Yuki; Shimoda, Haruko; Shide, Kotaro; Hidaka, Tomonori; Kitanaka, Akira; Yamashita, Kiyoshi; Matsuoka, Hitoshi; Shimoda, Kazuya
• Is Part Of: European journal of haematology. Volume 98:Number 5(2017:May)
• Page Start: 501
• Page End: 507
• Publication Date: 2017-03-10
• Subjects: adult T‐cell leukemia/lymphoma -- antibody therapy -- CC chemokine receptor 4 -- mogamulizumab -- retrospective; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; Blood -- Periodicals; 616.15005
• DOI: 10.1111/ejh.12863
• Languages: English
• ISSNs: 0902-4441

Abstract

Abstract: Objective: The efficacy of mogamulizumab in adult T‐cell leukemia/lymphoma (ATLL) was reported in a previous phase 2 study. Compared with patients in clinical trials, however, most patients in real‐life settings have demonstrated worse outcomes. Method: We retrospectively analyzed 96 patients with relapsed/refractory ATLL who received mogamulizumab treatment. Results: Relapsed/refractory ATLL patients with a median age of 70 years received a median of five courses of mogamulizumab. Hematologic toxicity and skin rash were the most common adverse events, and both were manageable. Of 96 patients, 87 were evaluable for efficacy. The overall response rate was 36%, and the median progression‐free survival (PFS) and overall survival (OS) from the start of mogamulizumab therapy were 1.8 and 4.0 months, respectively. Of the original 96 patients, only 25 fulfilled the inclusion criteria of the phase 2 study. Those who met the criteria demonstrated longer median PFS and OS durations of 2.7 and 8.5 months, respectively. The median OS from diagnosis in relapsed/refractory ATLL patients receiving mogamulizumab was 12 months, longer than the 5.8 months in a historical cohort without mogamulizumab. Conclusion: In clinical practice, mogamulizumab exhibited antitumor activity in patients with relapsed/refractory ATLL, with an acceptable toxicity profile. Mogamulizumab therapy improved the OS of ATLL patients.